Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

991 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SXZ, Khine HHTW, Itokawa N, Atsukawa M, Uojima H, Watanabe T, Takahashi H, Inoue K, Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, Toyoda H, Yu ML, Nguyen MH. Huang DQ, et al. Among authors: enomoto m. Hepatology. 2023 Nov 1;78(5):1558-1568. doi: 10.1097/HEP.0000000000000459. Epub 2023 May 16. Hepatology. 2023. PMID: 37184202
Favorable factors for re-treatment with pegylated interferon α2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus.
Tamori A, Kioka K, Kurai O, Sakaguchi H, Enomoto M, Fujii H, Kobayashi S, Iwai S, Morikawa H, Yamaguchi S, Kawasaki Y, Oka H, Tanaka Y, Kawada N. Tamori A, et al. Among authors: enomoto m. Hepatol Res. 2011 Dec;41(12):1169-77. doi: 10.1111/j.1872-034X.2011.00887.x. Epub 2011 Sep 26. Hepatol Res. 2011. PMID: 21951389
Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy, and efficacy of retreatment.
Kozuka R, Enomoto M, Hai H, Ogawa T, Nakaya M, Hagihara A, Fujii H, Kobayashi S, Iwai S, Morikawa H, Tamori A, Kawada N. Kozuka R, et al. Among authors: enomoto m. Hepatol Res. 2012 Dec;42(12):1157-67. doi: 10.1111/j.1872-034X.2012.01046.x. Epub 2012 Jun 3. Hepatol Res. 2012. PMID: 22672644
Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.
Hai H, Tamori A, Enomoto M, Morikawa H, Uchida-Kobayashi S, Fujii H, Hagihara A, Kawamura E, Thuy le TT, Tanaka Y, Kawada N. Hai H, et al. Among authors: enomoto m. J Gastroenterol Hepatol. 2014 Jan;29(1):201-7. doi: 10.1111/jgh.12376. J Gastroenterol Hepatol. 2014. PMID: 23980585
991 results